Table 3

Association between body size and body composition with prostate cancer

Gleason 6 PC

Gleason 7 PC

Gleason 8-10 PC

Measure

scale

n

OR

95% CI

n

OR

95% CI

OR

95% CI


BMI

per kg/m2

402

0.989

0.964, 1.015

272

1.025

0.997, 1.055

135

1.039

1.000,1.081

< 25

78

1.0

ref

55

1.0

ref

26

1.0

ref

25-29.9

198

1.17

0.85, 1.61

116

1.12

0.75, 1.64

62

1.63

0.90, 2.91

30-34.9

97

1.05

0.72, 1.51

66

1.24

0.80, 1.93

37

2.24

1.19, 4.23

≥ 35.0

29

0.96

0.57, 1.62

35

2.05

1.19, 1.93

10

1.41

0.54, 3.68

≥ 30 vs. < 30 (ref)

126

0.92

0.71, 1.19

101

1.33

0.98, 1.81

47

1.45

0.93, 2.25

WC

per cm

402

0.994

0.984, 1.004

272

1.012

1.002, 1.022

135

1.016

0.999,1.033

Q1

99

1.0

ref

66

1.0

ref

33

1.0

ref

Q2

106

1.07

0.76, 1.49

60

0.98

0.65, 1.49

27

1.22

0.65, 2.29

Q3

120

1.10

0.79, 1.53

75

1.18

0.79, 1.77

39

1.66

0.92, 2.98

Q4

77

0.94

0.65, 1.35

70

1.46

0.95, 2.23

36

1.90

1.03, 3.53

High vs. Low (ref)

197

1.00

0.78, 1.28

145

1.31

0.97, 1.75

75

1.59

1.04, 2.44

WHR

per 0.1 unit

402

0.898

0.756, 1.066

272

1.232

1.029, 1.474

135

1.034

0.769,1.388

Q1

100

1.0

ref

51

1.0

ref

29

1.0

ref

Q2

112

0.99

0.71, 1.37

61

0.98

0.63, 1.51

37

1.04

0.57, 1.88

Q3

85

0.85

0.60, 1.21

79

1.44

0.94, 2.20

24

0.88

0.47, 1.67

Q4

105

0.86

0.61, 1.21

80

1.25

0.81, 1.92

45

1.11

0.61, 2.00

High vs. Low (ref)

190

0.86

0.68. 1.10

159

1.36

1.01, 1.83

69

0.98

0.65, 1.49

FM

per kg

402

0.993

0.981, 1.004

271

1.010

0.997, 1.024

135

1.020

1.004,1.037

Q1

105

1.0

ref

63

1.0

ref

35

1.0

ref

Q2

111

1.09

0.79, 1.51

67

1.17

0.77, 1.78

24

0.99

0.52, 1.88

Q3

100

1.00

0.71, 1.39

67

1.34

0.88, 2.05

40

2.18

1.22, 3.87

Q4

86

0.88

0.62, 1.25

75

1.52

1.00, 2.30

36

1.65

0.90, 3.03

High vs. Low (ref)

186

0.90

0.71, 1.15

142

1.32

0.98, 1.77

76

1.93

1.25, 2.97

FFM

per kg

402

1.006

0.991, 1.021

271

1.029

1.011, 1.048

135

1.047

1.021,1.074

Q1

100

1.0

ref

78

1.0

ref

38

1.0

ref

Q2

96

0.98

0.70, 1.38

63

1.01

0.68, 1.51

25

1.11

0.59, 2.06

Q3

118

1.42

1.02, 1.99

60

1.16

0.76, 1.76

38

2.42

1.34, 4.39

Q4

88

1.14

0.80, 1.64

71

1.72

1.14, 2.61

33

2.91

1.56, 5.44

High vs. Low (ref)

206

1.31

1.02, 1.67

131

1.40

1.04, 1.89

71

2.50

1.60, 3.91

%BF

per%

402

0.985

0.968, 1.004

272

1.002

0.980, 1.025

135

1.017

0.987, 1.048

Q1

108

1.0

ref

60

1.0

ref

36

1.0

ref

Q2

109

0.99

0.72, 1.38

68

1.29

0.85, 1.96

26

1.05

0.57, 1.93

Q3

108

1.04

0.75, 1.44

84

1.63

1.08, 2.45

40

1.65

0.94, 2.92

Q4

77

0.71

0.50, 1.02

60

1.07

0.70, 1.65

33

1.21

0.66, 2.19

High vs. Low (ref)

185

0.88

0.69, 1.12

144

1.18

0.88, 1.58

73

1.39

0.92, 2.12


All analyses adjusted for age (years), PSA (ng/ml), prostate volume (ml), race (white, non-white), family history (Yes, No/unsure), and current treatment for diabetes, CVD, BPH, or hyperlipidemia. Q = quartile. High vs Low defined at median value

Fowke et al. BMC Cancer 2012 12:23   doi:10.1186/1471-2407-12-23

Open Data